Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
37.53 USD +1.73% Intraday chart for 10x Genomics, Inc. -1.24% -32.93%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
10x Genomics, Inc. Commercially Launches Visium HD Spatial Gene Expression Assay CI
10X Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel CI
10x Genomics Launches Two New Products With Single Cell Technology MT
10x Genomics, Inc. Begins Commercial Shipments of Chromium GEM-X Products CI
Transcript : 10x Genomics, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 02:50 PM
UBS Adjusts 10x Genomics Price Target to $52 From $44, Maintains Neutral Rating MT
Stifel Cuts Price Target on 10x Genomics to $63 From $68, Maintains Buy Rating MT
10x Genomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
10x Genomics Q4 Net Loss Widens, Revenue Increases; Issues Outlook MT
Earnings Flash (TXG) 10X GENOMICS Reports Q4 Revenue $184M, vs. Street Est of $183.7M MT
Transcript : 10x Genomics, Inc., Q4 2023 Earnings Call, Feb 15, 2024
10x Genomics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
10X Genomics, Inc. Provides Revenue Guidance for the Full Year 2024 CI
10x Genomics, Inc. Expands Leadership in Single Cell Analysis with Launch of GEM-X Technology CI
Transcript : 10x Genomics, Inc. Presents at 2024 AGBT General Meeting, Feb-07-2024 01:10 PM
NanoString Starts Chapter 11 Bankruptcy; Exploring Strategic Options, Including Potential Sale MT
Barclays Adjusts Price Target on 10x Genomics to $55 From $45, Maintains Overweight Rating MT
James Wilbur to Depart from 10X Genomics, Inc. as Chief Commercial Officer, Effective from February 1, 2024 CI
Transcript : 10x Genomics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 09:00 AM
10x Genomics Reports Preliminary Q4, Full Year 2023 Revenue MT
10x Genomics Launches Network to Accelerate Access to Xenium Proof-of-Concept Data MT
Wolfe Research Initiates 10x Genomics With Outperform Rating With $55 Price Target MT
North American Morning Briefing : Traders Await -2- DJ
BofA Securities Upgrades 10x Genomics to Neutral From Underperform, Adjusts Price Target to $54 From $36 MT
10x Genomics Insider Sold Shares Worth $619,494, According to a Recent SEC Filing MT
Chart 10x Genomics, Inc.
More charts
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, and others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
37.53 USD
Average target price
57.79 USD
Spread / Average Target
+53.97%
Consensus
  1. Stock
  2. Equities
  3. Stock 10x Genomics, Inc. - Nasdaq
  4. News 10x Genomics, Inc.
  5. 10x Genomics : BofA Securities Downgrades 10x Genomics to Neutral from Buy, Sets $180 Price Target